...
首页> 外文期刊>Clinical and experimental pharmacology & physiology >Effect of heparin on activation of platelet function in patients during radiofrequency catheter ablation.
【24h】

Effect of heparin on activation of platelet function in patients during radiofrequency catheter ablation.

机译:肝素对射频导管消融期间患者血小板功能激活的影响。

获取原文
获取原文并翻译 | 示例

摘要

1. Thromboembolism occurs in 0.4-2.0% of patients undergoing radiofrequency catheter ablation (RFCA). Some studies have shown that treatment with heparin inhibits the activation of coagulation and fibrinolysis. No study has directly measured the activation of platelet aggregation to investigate the effect of heparin on platelet function. The purpose of the present study was to observe the inhibitory effect of heparin on platelet activity in patients undergoing RFCA. 2. Sixty-two patients with supraventricular tachycardia were observed and divided into a heparin-treatment group and a control group. Changes in platelet aggregability (PAG) and thromboxane B(2) (TXB(2)) in the blood samples of all patients at different times (before, after electrophysiological study, immediately after and 10 and 30 min after the RFCA procedure) were observed. 3. No indication of clinically symptomatic thromboembolism and no major differences in baseline characteristics and procedure were apparent in either group. The levels of PAG and TXB(2) were all clearly increased after the electrophysiological study (all P < 0.05). Immediately after RFCA, PAG and TXB(2) levels were significantly increased in both groups and remained elevated 30 min after the procedure (all P < 0.05). In the heparin-treatment group, the increases in PAG (54.69 +/- 3.24%) and TXB(2) (29.01 +/- 1.84%) caused by RFCA were lower than changes observed in the control group (70.92 +/- 3.45 and 44.70 +/- 3.28%, respectively; both P < 0.01). Moreover, treatment with heparin normalized the elevated level of PAG 30 min after RFCA more clearly. 4. The results of the present study suggest that intravenous heparin treatment during the operation inhibits the activation of platelets induced by RFCA.
机译:1.接受射频导管消融(RFCA)的患者中有0.4-2.0%发生血栓栓塞。一些研究表明,用肝素治疗可抑制凝血和纤维蛋白溶解的激活。没有研究直接测量血小板聚集的激活来研究肝素对血小板功能的影响。本研究的目的是观察肝素对RFCA患者血小板活性的抑制作用。 2.观察到62例室上性心动过速患者,分为肝素治疗组和对照组。观察了所有患者在不同时间(在进行电生理学检查之前,在RFCA手术之后,10分钟和30分钟之后)血样中血小板凝集性(PAG)和血栓烷B(2)(TXB(2))的变化。 。 3.两组均无临床症状性血栓栓塞的迹象,基线特征和程序无明显差异。电生理研究后,PAG和TXB(2)的含量均明显增加(所有P <0.05)。 RFCA后,两组的PAG和TXB(2)水平立即显着升高,并在手术后30分钟保持升高(所有P <0.05)。在肝素治疗组中,RFCA引起的PAG(54.69 +/- 3.24%)和TXB(2)(29.01 +/- 1.84%)的升高低于对照组(70.92 +/- 3.45)和44.70 +/- 3.28%;两者均P <0.01)。此外,用肝素治疗可在RFCA后30分钟更清楚地使PAG的升高水平正常化。 4.本研究结果提示,术中静脉给予肝素治疗可抑制RFCA诱导的血小板活化。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号